about
Oral fumaric acid esters for psoriasisOral fumaric acid esters for psoriasisTopical therapies for the treatment of plaque psoriasis: systematic review and network meta-analysesTerminal epidermal differentiation is regulated by the interaction of Fra-2/AP-1 with Ezh2 and ERK1/2Re-evaluation of the diagnosis of porphyria cutanea tarda in Admiral Sir Francis Beaufort.A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy.Clinical, Quality of Life, Patient Adherence, and Safety Outcomes of Short-Course (12 Weeks) Treatment with Cyclosporine in Patients with Severe Psoriasis (the Practice Study).Treatment of severe psoriasis with infliximab.MicroRNAs: novel regulators in skin inflammation.Epigenetics and dermatological disease.Adherence to guidelines in the use of biological agents to treat psoriasis in Brazil.How genetic variation affects patient response and outcome to therapy for psoriasis.Hepatotoxicity related to antirheumatic drugs.Plants and plant products with potential antipsoriatic activity--a review.Stem cells behind the barrier.The Inflammatory Response in Psoriasis: a Comprehensive Review.Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region.Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study.End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome.Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting.MicroRNA-520a suppresses the proliferation and mitosis of HaCaT cells by inactivating protein kinase B.Balneotherapy in Psoriasis Rehabilitation.Monitoring treatment response in psoriasis: current perspectives on the clinical utility of reflectance confocal microscopy.
P2860
Q24187957-C0680389-FCAD-4C55-B53F-D9389C073E88Q24198185-361B56E2-F589-489A-8440-A26529155763Q27003961-0D4B3927-2ACA-4623-80E2-E86040836A09Q28589232-E2278D35-94E7-45BD-A55F-CBEA6166FD03Q34321214-5B9A5EAE-708A-4BB2-8A0E-E299F4A6D87FQ35205458-8DB08A5F-E6C6-4CFA-A594-249D9770726FQ36640532-D6906E97-9CD7-4D10-829C-BCAA77DE4212Q37098135-E9625A13-95E5-452D-9C8A-97F86A7D2F15Q37141220-7807A775-0D84-42A1-A31F-74FF3B720B0CQ37346201-C80A957D-DA0A-4D8D-AA3D-C61393BBABA9Q37628279-4A740E5E-6D78-407F-9F6C-31E942343AB1Q37803415-F027E50D-85D8-4D5C-BC75-2A8E1A47E76BQ37832129-DCEB85D6-1E41-41B6-85EE-DF4A7468E0C4Q38042746-71400F4A-90C8-42BE-AD89-AF0932FEB334Q38118084-1DC18DA4-F47F-4546-BB49-96CEBD8BE986Q38792930-02389C5A-7D7E-451F-85CC-4046AC0FD14AQ38838470-1F1291EE-9F14-485A-AD89-62844FC08E66Q39793030-D6F989D9-F234-448C-83B7-154DD8A907CCQ46699120-56188506-B9BF-4411-BE9C-1B2D5EE27C0BQ46735206-31902FD6-687F-4F0F-B8EA-C0E33E0E881DQ47097957-248D0BDA-6A3B-4135-BE53-FEF1832CCD50Q47441368-A3A99CF5-EA14-40F3-ADED-4CB5921660F8Q52701373-6397E1CB-CB95-4CE0-94AB-0A17B508E8C7
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Psoriasis and its management
@ast
Psoriasis and its management
@en
Psoriasis and its management
@nl
type
label
Psoriasis and its management
@ast
Psoriasis and its management
@en
Psoriasis and its management
@nl
prefLabel
Psoriasis and its management
@ast
Psoriasis and its management
@en
Psoriasis and its management
@nl
P2860
P356
P1433
P1476
Psoriasis and its management
@en
P2093
J N W N Barker
P2860
P304
P356
10.1136/BMJ.333.7564.380
P407
P577
2006-08-01T00:00:00Z